Trial Profile
A Phase 2a Study Evaluating the Safety and Efficacy of THVD-102, a combination of Oxybutynin and Pilocarpine, in Subjects with Primary Focal Hyperhidrosis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Oxybutynin/pilocarpine (Primary) ; Oxybutynin
- Indications Hyperhidrosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors TheraVida
- 03 Apr 2018 Status changed from active, no longer recruiting to completed, according to a Dermavant Sciences media release.
- 27 Feb 2017 Results published in a TheraVida Media Release.
- 27 Feb 2017 Results were published in the February 2017 issue of the Journal of Drugs in Dermatology, according to a TheraVida media release.